Biotime Inc (BTX) investors sentiment decreased to 1.19 in Q4 2018. It’s down -0.20, from 1.39 in 2018Q3. The ratio is negative, as 37 active investment managers started new and increased holdings, while 31 decreased and sold stakes in Biotime Inc. The active investment managers in our database now possess: 52.79 million shares, down from 55.13 million shares in 2018Q3. Also, the number of active investment managers holding Biotime Inc in top ten holdings was flat from 2 to 2 for the same number . Sold All: 10 Reduced: 21 Increased: 22 New Position: 15.
The stock decreased 1.67% or $0.02 during the last trading session, reaching $1.18. About 478,340 shares traded. BioTime, Inc. (BTX) has declined 42.59% since May 9, 2018 and is downtrending. It has underperformed by 46.96% the S&P500. Some Historical BTX News: 27/04/2018 – Asterias Biotherapeutics to Present AST-OPC1 Program Update at the Upcoming American Society for Neural Therapy and Repair Conference; 24/05/2018 – BIOTIME INC – EXPANSION OF ONGOING PHASE l/llA CLINICAL TRIAL FOR OPREGEN, WITH ADDITION OF TWO NEW U.S. SITES; 07/03/2018 – BIOTIME REPORTS DSMB OK TO PROCEED TO COHORT 4 OF OPREGEN TRIAL; 13/03/2018 – BioTime Submits CE Mark Application for European Approval of Renevia®; 01/05/2018 – BioTime Presents Updated OpRegen® Clinical Trial Data at ARVO; 01/05/2018 – BioTime: Signs of Structural Improvement in the Retina; 27/03/2018 – BIOTIME – UPON TERMINATION OF ESCROW, AGEX WILL RECEIVE REMAINDER OF CONSIDERATION SUBJECT TO DEDUCTIONS OF LIABILITIES AND/OR EXPENSES FROM ESCROW; 27/03/2018 – BIOTIME REPORTS CASH SALE OF ASCENDANCE BIOTECHNOLOGY; 25/04/2018 – BioTime Non-Deal Roadshow Scheduled By Chardan for May. 2; 16/04/2018 – Data from BioTime’s OpRegen® and Retinal Restoration Programs to Be Presented at ARVO 2018
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. The company has market cap of $176.58 million. The Company’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. It currently has negative earnings. The firm also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer.
Broadwood Capital Inc holds 3.84% of its portfolio in BioTime, Inc. for 29.97 million shares. Prescott General Partners Llc owns 1.85 million shares or 0.07% of their US portfolio. Moreover, Dafna Capital Management Llc has 0.05% invested in the company for 100,000 shares. The California-based Destination Wealth Management has invested 0.03% in the stock. Indexiq Advisors Llc, a New York-based fund reported 781,328 shares.
More notable recent BioTime, Inc. (NYSEAMERICAN:BTX) news were published by: Businesswire.com which released: “BioTime Reports First Quarter 2019 Financial Results and Provides Business Update – Business Wire” on May 09, 2019, also Businesswire.com with their article: “BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019 – Business Wire” published on May 03, 2019, Businesswire.com published: “AgeX Therapeutics, Inc. Shares Commence Trading on the NYSE American – Business Wire” on November 29, 2018. More interesting news about BioTime, Inc. (NYSEAMERICAN:BTX) were released by: Globenewswire.com and their article: “BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase – GlobeNewswire” published on January 04, 2019 as well as Businesswire.com‘s news article titled: “BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company – Business Wire” with publication date: November 08, 2018.
Analysts await Stepan Company (NYSE:SCL) to report earnings on July, 24. They expect $1.37 EPS, down 0.72% or $0.01 from last year’s $1.38 per share. SCL’s profit will be $30.99M for 16.39 P/E if the $1.37 EPS becomes a reality. After $1.31 actual EPS reported by Stepan Company for the previous quarter, Wall Street now forecasts 4.58% EPS growth.
A calculated and judicious act was made by the VP & Chief Financial Officer of Stepan Co, Mr. Luis Rojo, on 09/05/2019, when he acquired 250 shares, totalling $22,059 USD, based on an avg price of $88.2 of a share. He also acquired 250 shares worth about $22,393 USD in the last month. Luis Rojo right now owns 0.01% of the market cap of the Company.
Stepan Company, together with its subsidiaries, produces and sells specialty and intermediate chemicals to other manufacturers for use in various end products worldwide. The company has market cap of $2.03 billion. It operates in three divisions: Surfactants, Polymers, and Specialty Products. It has a 19.83 P/E ratio. The Surfactants segment offers surfactants that are used as principal ingredients in consumer and industrial cleaning products, such as detergents for washing clothes, dishes, carpets, floors, and walls, as well as shampoos and body washes; and other applications, including fabric softeners, germicidal quaternary compounds, and lubricating ingredients, as well as emulsifiers for spreading agricultural products and industrial applications, such as latex systems, plastics, and composites.
Since November 29, 2018, it had 5 insider buys, and 3 selling transactions for $256,289 activity. The insider Rojo Luis bought 200 shares worth $18,174. Slone Robert Victor sold $300,473 worth of Stepan Company (NYSE:SCL) on Thursday, November 29. Stefaniak Debra sold $15,975 worth of stock or 200 shares.
The stock increased 1.68% or $1.48 during the last trading session, reaching $89.8. About 83,760 shares traded. Stepan Company (NYSE:SCL) has risen 15.86% since May 10, 2018 and is uptrending. It has outperformed by 11.49% the S&P500. Some Historical SCL News: 20/04/2018 – Stepan Forms Golden Cross: Technicals; 24/04/2018 – STEPAN CO – HEADWINDS IN NORTH AMERICA POLYMER BUSINESS “WILL CONTINUE TO CHALLENGE US IN 2018”; 24/04/2018 – Stepan 1Q Adj EPS $1.37; 20/04/2018 – DJ Stepan Company, Inst Holders, 1Q 2018 (SCL); 10/04/2018 – STEPAN CO SCL.N – ROJO WILL SUCCEED MATTHEW EAKEN; 10/04/2018 – STEPAN CO SAYS ROJO WILL SUCCEED MATTHEW EAKEN – SEC FILING; 10/04/2018 – STEPAN CO SCL.N – MATTHEW EAKEN WILL CONTINUE IN HIS ROLE AS VICE PRESIDENT AND CORPORATE CONTROLLER; 27/03/2018 Stepan Completes Acquisition of a Surfactant Production Facility and a Portion of its Associated Surfactant Business in Mexico; 10/04/2018 – STEPAN REPORTS APPOINTMENT OF NEW VP & CFO; 24/04/2018 – STEPAN CO SCL.N – FOR FULL YEAR, COMPANY EXPECTS CAPITAL SPENDING TO BE BETWEEN $105 MLN AND $115 MLN
More notable recent Stepan Company (NYSE:SCL) news were published by: Finance.Yahoo.com which released: “Is Stepan Company (NYSE:SCL) Excessively Paying Its CEO? – Yahoo Finance” on May 03, 2019, also Seekingalpha.com with their article: “Stepan Company 2019 Q1 – Results – Earnings Call Slides – Seeking Alpha” published on April 30, 2019, Finance.Yahoo.com published: “Stepan Co (SCL) Q1 2019 Earnings Call Transcript – Yahoo Finance” on April 30, 2019. More interesting news about Stepan Company (NYSE:SCL) were released by: Prnewswire.com and their article: “Stepan Reports First Quarter Earnings – PRNewswire” published on April 30, 2019 as well as Globenewswire.com‘s news article titled: “Consolidated Research: 2019 Summary Expectations for Stepan, Helius Medical Technologies, ReWalk Robotics, Funko, Alimera Sciences, and Eyenovia â€” Fundamental Analysis, Key Performance Indications – GlobeNewswire” with publication date: April 18, 2019.
Investors sentiment decreased to 0.95 in Q4 2018. Its down 0.55, from 1.5 in 2018Q3. It fall, as 16 investors sold Stepan Company shares while 60 reduced holdings. 22 funds opened positions while 50 raised stakes. 16.20 million shares or 8.83% more from 14.88 million shares in 2018Q3 were reported. California State Teachers Retirement Sys reported 31,729 shares or 0.01% of all its holdings. Public Employees Retirement Of Ohio holds 30,939 shares or 0.01% of its portfolio. Moreover, Jacobs Levy Equity has 0.11% invested in Stepan Company (NYSE:SCL) for 84,762 shares. Lsv Asset Management holds 0.02% of its portfolio in Stepan Company (NYSE:SCL) for 122,736 shares. Acadian Asset Management Ltd Liability Com reported 28,733 shares. Riverhead Cap Mgmt Ltd Liability Company holds 0% of its portfolio in Stepan Company (NYSE:SCL) for 1,486 shares. Legal & General Grp Public Llc holds 0% of its portfolio in Stepan Company (NYSE:SCL) for 47,524 shares. Great West Life Assurance Can stated it has 0.01% of its portfolio in Stepan Company (NYSE:SCL). Mutual Of America Cap Mgmt Ltd Liability Com owns 506 shares or 0% of their US portfolio. Bluemountain Cap Mngmt Lc owns 0.02% invested in Stepan Company (NYSE:SCL) for 7,703 shares. Massachusetts-based Wellington Mngmt Gp Limited Liability Partnership has invested 0.01% in Stepan Company (NYSE:SCL). Voya Mngmt Ltd Co stated it has 28,588 shares or 0.01% of all its holdings. Los Angeles Cap Mngmt & Equity Research has 0% invested in Stepan Company (NYSE:SCL). Goldman Sachs holds 0% of its portfolio in Stepan Company (NYSE:SCL) for 77,397 shares. Dean Investment Associate Lc holds 30,460 shares.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.